跳至主要内容
临床试验/NL-OMON41255
NL-OMON41255已完成3 期

A randomized, double-blind, parallel group, multicentre phase IIIb study to compare ticagrelor with clopidogrel treatment on the risk of cardiovascular death, myocardial infarction and ischemic stroke in patients with established Peripheral Artery Disease (EUCLID Examining Use of tiCagreLor In paD) - EUCLID

Astra Zeneca0 个研究点目标入组 225 人开始时间: 待定最近更新:

试验速览

阶段
3 期
状态
已完成
发起方
入组人数
225

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
18 至 99(—)

入选标准

  • 1. Male and Female patients 50 years old or older
  • 2. Symptomatic peripheral artery disease;For other inclusion criteria see protocol page 31.

排除标准

  • 1. Patients needing dual anti-platelet drug treatment before start of study
  • 2. Planned revascularisation or amputation
  • 3. Patients with known bleeding disorders
  • 4. Patients with a history of intracranial bleed
  • 5. Patients considered to be at risk of bradycardic events unless already treated with a permanent pacemaker;For other exclusion criteria see protocol page 31-33.

研究者

发起方
Astra Zeneca

相似试验